Treatment of hemochromatosis;Traitement de l'hémochromatose

Medecine Therapeutique

Volumn 7, Issue 5, 2001, Pages 356-360

  Moirand, R ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE MESYLATE;

BONE MALFORMATION; GENETIC PREDISPOSITION; HEMOCHROMATOSIS; HYPOGONADISM; PHENOTYPE; PHLEBOTOMY; REVIEW; TREATMENT INDICATION;

EID: 0034928993     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis
2. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy
3. Current status of iron chelation therapy with desferrioxamine
4. Ascorbic acid status in idiopathic hemochromatosis
5. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: An electrophysiological study of cerebral and visual function
6. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA
7. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalasssemia major
8. Reduction of tissue iron stores and normalization of serum ferritin concentration during treatment with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalasssemia intermedia
9. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis
10. Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy
11. Long-term survival analysis in hereditary hemochromatosis
12. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis
13. Long-term survival in patients with hereditary hemochromatosis
14. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis
15. Primary liver cancer in genetic hemochromatosis: A clinical, pathological, and pathogenetic study of 54 cases
16. Cardiac hemochromatosis: Beneficial effects of iron removal therapy. An echocardiographic study
17. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis
18. Liver transplantation in idiopathic hemochromatosis
19. Orthotopic liver transplantation for hemochromatosis
20. Testosterone treatment of men with idiopathic hemochromatosis
21. The principles and practice of screening for disease
22. Faut-il dépister l'hémochromatose? Une analyse critique de la littérature
23. Neonatal screening for the hemochromatosis defect
24. Prevalence of the C282Y mutation in Brittany: Penetrance of genetic hemochromatosis?
25. Clinical presentation of hemochromatosis: A changing scene
26. Homozygosity for hemochromatosis: Clinical manifestations
27. Phenotypic expression of the HFE mutations: A French study of 1 110 unrelated iron-overloaded patients and relatives
28. A genotypic study of 217 unrelated probands diagnosed as « genetic hemochromatosis » on « classical » phenotypic criteria
29. Screening for hemochromatosis in children of homozygotes: Prevalence and cost-effectiveness
30. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis